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In the pathogenesis of periodontitis, an infection-induced inflammatory disease of
the tooth-supporting tissues, there is a complex interaction between the subgingival
microbiota and host tissues. A periodontal diagnostic tool for detecting the initiation
and progression of the disease, monitoring the response to therapy, or measuring the
degree of susceptibility to future disease progression has been of interest for a long
time. The value of various enzymes, proteins, and immunoglobulins, which are abundant
constituents of saliva, as potential biomarkers has been recognized and extensively
investigated for periodontal diseases. Gingival defensins and cathelicidins are small
cationic antimicrobial peptides that play an important role in innate immune response.
However, their applicability as salivary biomarkers is still under debate. The present review
focuses on proteomic biomarkers and antimicrobial peptides, in particular, to be used at
early phases of periodontitis.
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PERIODONTITIS: AN ORCHESTRAL MASTERPIECE
Periodontitis, an infection-induced inflammatory disease of the tooth-supporting tissues, is
initiated by the formation of pathogenic biofilms at and under the gingival margin. Out of
more than 700 resident bacterial species of the oral cavity, about a half can be found in
subgingival biofilms in both healthy and diseased sites (Teles et al., 2006). Periodontitis-associated
pathogens and their toxins in bacterial biofilms perturb gingival epithelial cells triggering a
sequence of inflammatory and immune responses. The initial inflammatory response aims to limit
bacterial invasion by promoting the infiltration of neutrophils and macrophages to the site of
bacterial challenge. This infiltration is achieved by the secretion of proinflammatory cytokines and
chemokines from gingival epithelial cells and fibroblasts (Preshaw and Taylor, 2011). After their
migration to inflamed tissues, leukocytes suppress bacterial invasion by their oxygen dependent
or independent mechanisms. Subsequently, T- and B-cells emerge to the site of infection and
secrete immunoglobulins as an antigen-specific response. If the host defense fails to suppress
the level of infection by eliminating pathogens, continuing inflammation finally ends up in
alveolar bone destruction (Bartold and Narayanan, 2006; Preshaw and Taylor, 2011). In the course
of the disease, a number of matrix metalloproteases (MMPs), MMP-8, MMP-9, and MMP-13,
in particular, are produced and activated by host cells in a cascade leading to degradation of
gingival tissues and alveolar bone (Sorsa et al., 2004). Osteoclastogenesis is connected to an
increased expression of Receptor Activator for Nuclear Factor κB Ligand (RANKL) and a decreased
expression of osteoprotegerin in osteoblast cells. A consensus report of the 7th EuropeanWorkshop
on Periodontology recently highlighted interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α,
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and RANKL as important players in the periodontitis network
(Kinane et al., 2011). Therefore, it does not seem an exaggeration
to argue that rather than the bacterial infection, the magnitude of
the inflammatory response raised against pathogens seems to be
the determinant for developing a destructive periodontal disease
(Page and Kornman, 1997; Van Dyke, 2007; Silva et al., 2008).
Without an adequate therapy, chronic inflammation may result
in the destruction in the attachment between the tooth and the
gingival tissue, formation of periodontal pockets, alveolar bone
loss and, eventually, tooth loss (Darveau, 2010). Yet, this complex
interplay between the subgingival microbiota and host tissues is
not the same for everyone; several factors, such as smoking, age,
systemic disease, and genetic susceptibility, modify the formation
and progression of periodontal diseases (Marsh et al., 2011).
SALIVA AS A DIAGNOSTIC FLUID
In general, dental clinicians are looking for a diagnostic tool,
preferably a non-invasive one, to determine the current status of
periodontal disease, to monitor the response to therapy, and to
measure the degree of susceptibility to future disease progression
(Giannobile et al., 2009). Conventional diagnostic tools, such
as probing pocket depths, bleeding on probing, and clinical
attachment level, are inadequate to identify patients who are at
risk for disease progression (Goodson, 1992). Saliva has a major
importance in the maintenance of oral health, and, during the
past two decades, it has been considered a potential specimen to
detect oral and systemic diseases (Ji and Choi, 2015). Saliva as a
diagnostic fluid has been evaluated for detecting caries (Bratthall
and Hänsel Petersson, 2005), periodontitis (Christodoulides
et al., 2007; Gursoy et al., 2011), oral and breast cancer (Li et al.,
2004; Streckfus and Bigler, 2005), and hepatitis (Ohnishi and
Daikuhara, 2003).
With the development of different—omics technologies,
analysis of saliva has become particularly fascinating, not only in
dentistry but also in general medicine (Zhang et al., 2009; Cuevas-
Córdoba and Santiago-García, 2014). By analyzing an array of
constituents present in saliva, it is possible to estimate the risk
of disease onset, to monitor disease progression, and to evaluate
therapeutic efficacy of oral infections as well as oropharyngeal
lesions (Zhang et al., 2009).
SALIVARY BIOMARKERS OF
PERIODONTITIS: WHAT HAVE BEEN
FOUND SO FAR?
Specific biomarkers have been identified from saliva, reflecting
the three key features of pathogenic processes in periodontal
disease, i.e., infection-induced inflammation, collagen
degradation, and bone turnover (Zhang et al., 2009). Host-
and bacteria-derived enzymes, proteins, and other inflammatory
mediators appear to hold great promise as salivary biomarkers
for the diagnosis of periodontal disease (Giannobile et al., 2009).
In infected periodontal tissues, numerous cytokines are secreted
as part of the innate response by resident cells (epithelial cells,
fibroblasts) and neutrophils. There is strong evidence to suggest
that salivary IL-1β is a relevant biomarker of periodontitis, while
no significant association has been found between salivary TNF-
α or IL-6 levels and the presence of periodontitis (Gursoy et al.,
2009; Ebersole et al., 2013; Taylor, 2014). Host-derived MMPs
are considered initiators of the extracellular matrix degradation
associated with periodontitis (Sorsa et al., 1990; Uitto et al.,
1990). Especially MMP-8, a neutrophil collagenase, has the
potential to be used as a biomarker of periodontal destruction.
In a number of studies, it has been shown that MMP-8 activity
is elevated in saliva of periodontitis patients as compared to
their periodontally healthy controls, regardless of study subjects’
smoking status (Sorsa et al., 2004; Miller et al., 2006; Gursoy
et al., 2010).
ANTIMICROBIAL PEPTIDES: FUNCTIONS
AND INTERACTIONS IN PERIODONTAL
TISSUES
The oral cavity with its various surfaces offers an open
environment, which allows a constant exposure of
microorganisms to be colonized and, in favorable circumstances,
this can lead to disease (Diamond et al., 2008). Bacterial infection
in the mouth is resisted by the stratified squamous epithelium,
which acts as a mechanical barrier, and saliva provides a
mechanical rinsing action (Gorr, 2012). The oral epithelium and
saliva are the most central defense systems in the mouth. These
two defense systems do not act as passive protectionmechanisms,
but both of them contain several types of antimicrobial peptides,
including histatins, defensins, and hCAP18/LL-37 (De Smet
and Contreras, 2005). Antimicrobial peptides are small cationic
peptides with a broad spectrum of antimicrobial activity. A
complex mixture of over 45 antimicrobial proteins and peptides
are found in oral fluids (Denny et al., 2008); of these, 13 are up-
regulated in periodontal disease, while 11 are down-regulated.
Defensins and hCAP18/LL-37 belong to key components of the
mucosal antimicrobial defense (Hosokawa et al., 2006; Gorr,
2012).
Defensins are divided into subfamilies of α- and β-defensins
(Table 1). These defensins differ in their cysteine motifs, but
share a similar secondary structure, and both of them are rich
in cationic residues (Beckloff and Diamond, 2008). Four types
of α-defensins [Human Neutrophilic Peptide (HNP) 1-4] are
found predominantly in neutrophils (Ganz et al., 1985), whereas
human β-defensins (hBDs) are mainly produced by epithelial
cells (Gursoy and Könönen, 2012). The number of hBDs has
been suggested to be over 20 based on genomic targeting (Lehrer,
2011). Of the four hBDs known so far, hBD 1-3 are expressed and
secreted in the human oral cavity (Dale and Krisanaprakornkit,
2001; Vardar-Sengul et al., 2007). The sole human cathelicidin,
hCAP18/LL-37, was initially identified in infiltrating neutrophils
in the oral cavity (Dale and Krisanaprakornkit, 2001). However, it
has been observed in the salivary glands and gingival epithelium
as well (Woo et al., 2003; Gursoy et al., 2012).
Antimicrobial peptides play a major role in the innate
host defense. HNPs, hCAP18/LL-37, and hBDs exhibit a
broad-spectrum antimicrobial activity against Gram-positive
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TABLE 1 | Comparisons between human β-defensins (hBDs) and human α-defensins (human neutrophil peptides, HNPs).
Expressed and
secreted by
Associations with common oral
diseases
Activation in periodontal tissues Regulatory effects on other
host-cells and tissues
Human β-defensins (hBDs) Epithelial cells Caries and periodontitis, oral
cancers
hBD-1 is secreted constitutively, while
infection and inflammation influence
the secretions of hBD-2 and hBD-3
Chemoattraction of dendritic and
T cells, macrophages; wound
healing in epithelium
Human α-defensins (HNPs) Neutrophils Periodontitis, oral cancers Synthesized in promyelocytes and
myelocytes as proHNPs and stored
as mature HNPs in azurophil granules
before they reach to periodontal
tissues
Epithelial cell viability, adhesion,
spread
and -negative bacteria, fungi, and enveloped viruses (Gomes Pde
and Fernandes, 2010). Like HNPs, hBDs are considered to exert
their antibacterial effect by permeabilizing the bacterial cellular
membrane. In addition to their direct antimicrobial activity, both
HNPs and hBDs exhibit numerous other biological activities
(Dommisch and Jepsen, 2015). HNP 1-3 and hBD 1-3 have a
selective chemotactic activity for a variety of host defense cells
like immature dendritic cells and mast cells (Soruri et al., 2007).
They function as both proinflammatory and anti-inflammatory
agents in the periodontal disease pathogenesis (Bowdish et al.,
2006). Besides their antimicrobial and immune regulatory
functions, hBDs contribute to the healing process of wounds
(Niyonsaba et al., 2007) and HNP-1 regulates epithelial cell
adhesion and spread (Gursoy et al., 2013). While initially isolated
as an antimicrobial peptide, hCAP18/LL-37 has been proposed
to play additional roles in inflammation. hCAP18/LL-37
demonstrates a chemotactic activity for neutrophils, monocytes,
and some T-cells. Furthermore, hCAP18/LL-37 affects dendritic
cell maturation (Kai-Larsen and Agerberth, 2008). Taken
together, these multiple activities of antimicrobial peptides
suggest that they play an important, multifunctional role in host
defense (Gorr and Abdolhosseini, 2011).
It is considered that HNPs, hBDs, and hCAP18/LL-37
have the same function in health and disease, but in a
coordinated manner. Periodontal infection and inflammation
is thought to affect the expression of each antimicrobial
peptide (Gursoy and Könönen, 2012). Up-regulated expression
of hBDs has been demonstrated in infections, inflammatory
stimulations, and keratinocyte differentiation. In non-inflamed
gingival tissues, both hBD-1 and hBD-2 are expressed; their
levels are highest at gingival margin close to dental plaque
(Yilmaz et al., 2015). During the inflammatory state, these
peptides are expressed also in the sulcular epithelium (Dale
and Krisanaprakornkit, 2001). The expression of hBD-3 is
primarily located in the basal layer of healthy gingival tissues,
but it is extended toward superficial layers of the gingival
epithelium in periodontitis (Lu et al., 2005; Yilmaz et al.,
2015). Although a number of studies have described expression
levels and localizations of hCAP18/LL-37, hBDs, and HNPs
in healthy and inflamed gingival tissues (Krisanaprakornkit
et al., 2000; Dale and Krisanaprakornkit, 2001; Dommisch
et al., 2005; Hosokawa et al., 2006; Kuula et al., 2008;
Brancatisano et al., 2011; Yilmaz et al., 2015), their relation to
the initiation and progression of periodontal disease is still poorly
understood.
INTERACTIONS BETWEEN SALIVA AND
ANTIMICROBIAL PEPTIDES: ROAD TO
BIOMARKERS
The main sources of antimicrobial peptides in the oral cavity
are the gingival epithelium and neutrophils, although salivary
glands also secrete some amounts of defensins and hCAP18/LL-
37 (Mathews et al., 1999; Mizukawa et al., 1999). By using high
performance liquid chromatography, it has been demonstrated
that healthy adults have a mean value of 0.5–0.9mg/ml HNP-
1 in whole saliva (Goebel et al., 2000). As a large number
of neutrophils continuously enter the oral cavity through the
junctional epithelium, it is possible that HNPs are mainly derived
from these neutrophils. Immunohistochemical staining for HNP
1-3 showed the presence of peptides in parts of the ductal cells
in submandibular glands and in minor salivary glands, while
no HNP was detected in an individual major salivary gland
(Mizukawa et al., 1999). This indicates that ductal cells can be a
source of HNPs in saliva (Abiko and Saitoh, 2007). The sources of
hBDs in saliva are assumed to be the oral epithelium and salivary
glands. hBD-1, -2, and -3 mRNA have been detected in salivary
glands, including the parotid, submandibular, and minor glands,
as well as the oral epithelium (Bonass et al., 1999; Dunsche et al.,
2001). The mean concentrations of hBD-1 and -2 in whole saliva
of healthy subjects are around 150 ng/ml (Mathews et al., 1999),
while that of hBD-3 is about 730 ng/ml (Abiko and Saitoh, 2007).
In humans, hCAP18/LL-37 is mainly secreted by neutrophils and
it is present in saliva at concentrations of 0.14–3µg/ml (Gorr,
2009).
Saliva carries a significant amount of antimicrobial peptides as
part of its defensemechanism but also impairs their antimicrobial
functions. As an example, saliva can reduce the antibacterial
activities of hBD 1-3 and hCAP18/LL-37 by 20–50% in in vitro
conditions (Mineshiba et al., 2003). This in vitro effect is generally
explained by the salt concentration of saliva. However, this
is probably unlikely because of the low salt concentrations in
saliva. Moreover, hBD activity in saliva may get affected by
proteases and redox enzymes. On the one hand, proteases, at least
in in vitro conditions, affect the activity and concentration of
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antimicrobial peptides (Kuula et al., 2008), thereby may reduce
their value to be used as salivary biomarkers of periodontal
disease. On the other hand, defensins are reduced by thioredoxin
reductases to their active forms. For instance, glutaredoxin can
reduce hBD-1 to its antibacterial form (Jaeger et al., 2013).
The activation or inactivation by other proteins in saliva can
have a significant effect on the use of antimicrobial peptides as
biomarkers, since a selected method for analysis may detect only
one form of the peptide, depending on the antibody chosen.
Therefore, interactions of antimicrobial peptides with other
proteins in saliva should be thoroughly analyzed (Wilson et al.,
1999).
ANTIMICROBIAL PEPTIDES AS SALIVARY
BIOMARKERS: HOW MUCH EVIDENCE DO
WE HAVE?
Although, the levels of single markers in saliva can be
statistically distinguished between subjects with and without
periodontitis, the large variation in their values between
individuals make a prospective assignment difficult (Miller
et al., 2010). Antimicrobial peptides are typically expressed
in response to oral bacteria or bacterial toxins, which makes
them suitable biomarkers for the diagnosis of periodontal
disease (Gorr, 2009; Gorr and Abdolhosseini, 2011). Information
on the association between salivary antimicrobial peptide
concentrations and periodontal disease status is limited. Pereira
et al. (2013) studied salivary levels of hBD-2 in 31 chronic
periodontitis and 27 gingivitis patients, compared to 31
periodontally healthy controls, and detected elevated hBD-2
levels in chronic periodontitis patients. No relationship between
the frequency of examined periodontopathogens and hBD-
2 protein concentrations was found. Salazar et al. (2013)
examined 20 periodontally healthy and 20 diseased subjects
to identify periodontitis-associated changes in the proteome
of the whole saliva. Twenty proteins, including HNP-1, were
elevated in periodontitis patients in comparison to their
controls (Salazar et al., 2013). It is important to note that
peptide concentrations can be significantly diluted in saliva
and, therefore, much lower than those in periodontal pockets
and gingival tissues (Gorr, 2012). Salivary LL-37 concentrations
have been demonstrated to correlate to periodontal tissue
destruction in subjects with chronic periodontitis (Takeuchi et al.,
2012).
Advances in genomic technologies offer hitherto
unprecedented observations on complex human diseases.
To date, however, there is only one study by Jaradat et al. (2013)
where associations between the genomic copy number of hBD-2
and periodontitis are evaluated. According to their results,
there is an association between decreased hBD-2 genomic
copy numbers and severity periodontitis. With increasing
information, it may be possible to avoid some of the limitations
that currently exist in the use of gingival defensins as biomarkers
of periodontitis. Moreover, the outcomes of genomic research
would help in understanding clinically distinct diseases, for
example Crohn’s disease, and periodontitis, with a view on their
shared molecular targets, such as hBD-2 (Keskin et al., 2015).
FIGURE 1 | Limitations in the use of antimicrobial defensins as salivary
biomarkers of periodontitis (T, Tooth; C, Connective Tissue; A, Alveolar
Bone; E, Epithelium; red dots, α-defensins; blue dots, β-defensins).
THINGS TO CONSIDER
In this review, we evaluated the evidence on salivary
antimicrobial peptides as biomarkers of periodontitis. These
small peptides form the initial tissue response against infection
and thus could function as an early diagnostic marker of
periodontitis. However, in the use of antimicrobial peptides
as biomarkers of periodontitis there are significant limitations
to consider, and the majority of these limitations are not fully
characterized (Figure 1). Firstly, antimicrobial peptides can
aggregate in a concentration dependent manner (Brogden,
2005), and this may weaken the sensitivity of test methods, such
as an enzyme-linked immunoassay (ELISA). It is also possible
that host-derived and bacterial enzymes degrade antimicrobial
peptides, decreasing the sensitivity of the methods depending
on the antibody of choice. Further, binding to bacterial
lipopolysaccharides and DNA may force salivary antimicrobials
to accumulate in the pellet at the initial centrifugation of the
sample. Finally, some antimicrobial peptides do not get out of
the tissue, but accumulate in the cell cytoplasm and cell nucleus
as recently described by Yilmaz et al. (2015). They may still be
protective against invading bacteria, however, their accumulation
tendency affects their concentrations in saliva that will not reflect
the degree of inflammation.
CONCLUSION
Despite the limitations, it can be concluded that salivary
antimicrobial peptides have potential to be considered as early
markers of periodontitis. The entire human salivary proteome
was reported by a consortium of three research groups,
revealing that 1166 proteins are present in human saliva (Denny
et al., 2008). In the pathogenesis of periodontitis, antimicrobial
peptides cooperate with other inflammatory proteins and
regulate distinct inflammatory pathways. Thus, a combinational
approach, in which antimicrobial peptides are measured together
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with their activators or target proteins, will increase their value
as diagnostic biomarkers. This aim may be achieved by newly
developed omics technologies.
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